Literature DB >> 4743334

The effect of noradrenaline on blood flow and oxygen consumption in normal and ischemic areas of myocardium.

R J Marhsall, J R Parratt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4743334     DOI: 10.1016/0002-8703(73)90343-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  7 in total

1.  Antiarrhythmic, haemodynamic and metabolic effects of 3alpha-amino-5alpha-androstan-2beta-ol-17-one hydrochloride in greyhounds following acute coronary artery ligation.

Authors:  R J Marshall; J R Parratt
Journal:  Br J Pharmacol       Date:  1975-11       Impact factor: 8.739

2.  Comparative effects of propranolol and practolol in the early stages of experimental canine myocardial infarction.

Authors:  R J Marshall; J R Parratt
Journal:  Br J Pharmacol       Date:  1976-06       Impact factor: 8.739

3.  The effect of dilazep on blood flow and oxygen handling in the early stages of canine myocardial infarction. Simultaneous comparison with changes in the normal myocardium.

Authors:  R J Marshall; J R Parratt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

4.  The haemodynamic and metabolic effects of MG 8926, a prospective antidysrhythmic and antianginal agent.

Authors:  R J Marshall; J R Parratt
Journal:  Br J Pharmacol       Date:  1977-02       Impact factor: 8.739

5.  The beneficial actions of bepridil in acute myocardial infarction in anaesthetized dogs.

Authors:  R J Marshall; A W Muir
Journal:  Br J Pharmacol       Date:  1981-06       Impact factor: 8.739

6.  Cardiovascular effects of diethylcarbamazine citrate.

Authors:  A K Abaitey; J R Parratt
Journal:  Br J Pharmacol       Date:  1976-02       Impact factor: 8.739

7.  Effect of myocardial oxygen consumption on infarct size in experimental coronary artery occlusion.

Authors:  K D Müller; S Sass; M G Gottwik; W Schaper
Journal:  Basic Res Cardiol       Date:  1982 Mar-Apr       Impact factor: 17.165

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.